In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
The US Food and Drug Administration has extended its priority review period by up to three months for Swiss pharma giant Novartis’ New Drug Application of LBH589 (panobinostat). 25 November 2014
USA-based Amgen has terminated all company-sponsored clinical studies of rilotumumab in advanced gastric cancer, including the Phase III RILOMET-1 and RILOMET-2 studies. 24 November 2014
US drug major Bristol-Myers Squibb and protein therapeutics specialist Five Prime Therapeutics are to collaborate on the evaluation of combining Opdivo (nivolumab) and Five Prime’s FPA008. 24 November 2014
Researchers from the Medical University of Vienna, Austria, have clarified why using therapeutic agents to inhibit the epidermal growth factor receptor in liver cancer failed, when it was expected in recent years that the therapy would be an important milestone in oncology treatments. 24 November 2014
The vote against the recommendation that the US Food and Drug Administration approves Novartis’ panobinostat (Farydak) for use in relapsed/refractory multiple myeloma by the Oncologic Drugs Advisory Committee (ODAC) signals that a US marketing authorization is unlikely to be granted, according to an analyst. 21 November 2014
A survey carried out by Swiss drug major Roche has shown that frontline staff believe patient care is suffering as a result of cancer capacity challenges in the NHS. 21 November 2014
Johnson & Johnson/AstraZeneca’s Zytiga (abiraterone acetate) is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain and the UK (EU5). 20 November 2014
Chinese biotech firm 3SBio Inc has entered into an exclusive license with PharmAbcine for the development, manufacturing and marketing of tanibirumab, an anti-VEGFR2/KDR antibody for cancer. 20 November 2014
Personalized cancer therapy specialist Clovis Oncology has achieved positive results in a Phase II trial of rucaparib in ovarian cancer patients with tumor BRCA mutations. 20 November 2014
Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial analysts on the progress against the company’s strategic priorities of achieving scientific leadership and returning to growth. 18 November 2014
Germany’s Merck KGaA said today that it has entered into a global agreement with US pharma giant Pfizer to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck. 17 November 2014
US drug major Bristol-Myers Squibb has announced results from a study comparing Opdivo (nivolumab) to dacarbazine in patients with treatment naïve BRAF wild-type advanced melanoma. 17 November 2014
Swiss pharma major Roche has terminated its 2013 collaboration, option, and license agreement with US drug developer Inovio Pharmaceuticals to co-develop INO-5150, Inovio's DNA immunotherapy targeting prostate cancer, as well as their research collaboration in prostate cancer. 17 November 2014
The US Food and Drug Administration on Friday approved Avastin (bevacizumab) solution for intravenous infusion in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. 16 November 2014
Results published in the New England Journal of Medicine show that treatment with the combination of trametinib (Mekinist) and dabrafenib (Tafinlar) significantly improved overall survival (OS) compared to vemurafenib monotherapy in previously untreated patients with BRAF V600E/K mutation-positive metastatic melanoma, without increased overall toxicity. 16 November 2014
Onxeo, created by a merger between French company BioAlliance Pharma, and Danish biopharmaceutical company Topotarget, confirmed receipt of $25 million related to the approval of Beleodaq (belinostat). 14 November 2014
The Association of the British Pharmaceutical Industry has spoken out against imminent changes to how NHS England will re-evaluate the medicines currently offered under the Cancer Drugs Fund in the UK. 14 November 2014
Geron Corp has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, a subsidiary of US health care giant Johnson & Johnson, to develop and commercialize, imetelstat. 14 November 2014
The UK’s National Health Service has updated its procedure for evaluating drugs in the Cancer Drugs Fund, which it says means more effective and promising drugs will be prioritized and made available to patients. 13 November 2014
Cancer diagnostics and personalized medicines specialist ValiRx has agreed to collaborate with Deutsches Krebsforschungzentrum for further development of ValiRx’s proprietary Gene Inactivation through Chromatin Engineering technology platform. 13 November 2014